SCOPUS 정보 검색 플랫폼

Volumn 59, Issue 1, 2007, Pages 149-150

Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma

(3) Porta, Camillo a Mutti, Luciano b Tassi, Gianfranco c

a FONDAZIONE IRCCS POLICLINICO SAN MATTEO (Italy)

b Local Health Unit 11 (Italy)

c Civic Hospital (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR;

CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; DISEASE SEVERITY; DRUG TOLERABILITY; EDEMA; FATIGUE; HUMAN; ITALY; LETTER; LIFE EXPECTANCY; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEUTROPENIA; PILOT STUDY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; RASH; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PLEURAL NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STEM CELL FACTOR; TREATMENT FAILURE;

EID: 33751294371 PISSN: 03445704 EISSN: None Source Type: Journal
DOI: 10.1007/s00280-006-0243-4 Document Type: Letter

Times cited : (62)

References (6)

1
- 20644466217
- New agents in the management of malignant mesothelioma
- Vogelzang NJ, Porta C, Mutti L (2005) New agents in the management of malignant mesothelioma. Semin Oncol 32:336-350
- (2005) Semin Oncol , vol.32 , pp. 336-350
- Vogelzang, N.J.¹ Porta, C.² Mutti, L.³

2
- 2342466803
- The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: A study of 96 cases using single-source antibody with a review of the literature
- Butnor KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL (2004) The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using single-source antibody with a review of the literature Arch Pathol Lab Med 128:538-543
- (2004) Arch Pathol Lab Med , vol.128 , pp. 538-543
- Butnor, K.J.¹ Burchette, J.L.² Sporn, T.A.³ Hammar, S.P.⁴ Roggli, V.L.⁵

3
- 8744305031
- Induction of stem cell factor/C-kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells
- Catalano A, Rodilossi S, Rippo MR, Caprari P, Procopio A (2004) Induction of stem cell factor/C-kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells J Biol Chem 279:46706-46714
- (2004) J Biol Chem , vol.279 , pp. 46706-46714
- Catalano, A.¹ Rodilossi, S.² Rippo, M.R.³ Caprari, P.⁴ Procopio, A.⁵

4
- 20344372059
- A phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM)
- (abs.7200)
- Villano JL, Husain AN, Stadler WM, Hanson LL, Vogelzang NJ, Kindler HL (2004) A phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). Abs Am Assoc Clin Oncol 23:663 (abs. 7200)
- (2004) Abs Am Assoc Clin Oncol , vol.23 , pp. 663
- Villano, J.L.¹ Husain, A.N.² Stadler, W.M.³ Hanson, L.L.⁴ Vogelzang, N.J.⁵ Kindler, H.L.⁶

5
- 24744463358
- Limited efficacy of imatinib mesylate in malignant mesothelioma: A phase II trial
- Mathy A, Baas P, Dalesio O, van Zandwijk N (2005) Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial Lung Cancer 50:83-86
- (2005) Lung Cancer , vol.50 , pp. 83-86
- Mathy, A.¹ Baas, P.² Dalesio, O.³ Van Zandwijk, N.⁴

6
- 20644462328
- STI571 and gemcitabine combined cell treatment as a novel approach to malignant mesothelioma therapy
- Abs
- Cacciotti P, Barbone D, Porta C, Mutti L, Gaudino G (2004) STI571 and gemcitabine combined cell treatment as a novel approach to malignant mesothelioma therapy. Abs. VII meeting of the International Mesothelioma Interest Group (IMIG), p 99
- (2004) VII Meeting of the International Mesothelioma Interest Group (IMIG) , pp. 99
- Cacciotti, P.¹ Barbone, D.² Porta, C.³ Mutti, L.⁴ Gaudino, G.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.